"Efficiency and cost savings were themes repeated often at the annual conference of the Colorado BioScience Association.
Once upon a time, it was enough for biotech firms to show how innovative their latest offerings were, even if they weren't fully proven and they cost more than whatever they were replacing.
After the passage of the Affordable Care Act, proof something works matters more than its whiz bang. And anything new needs to cut costs rather than inflate them.
'It needs to be a better and less-expensive solution,' said Bill Aldrich, CEO of EndoShape, a Boulder start-up that is developing polymer plugs and coils designed to replace more expensive platinum products now in use in blood vessels."
Link to the full article at DenverPost.com
No comments:
Post a Comment